Phage Therapy for the Prevention and Treatment of Pressure Ulcers.

Phase 1

• Conditions: Pressure Ulcer
• Interventions: Combination Product: Placebo; Combination Product: Bacteriophage-loaded Microcapsule Spray; Procedure: Standard of Care

• Registration Number: NCT04815798
• Lead Sponsor: Precisio Biotix Therapeutics, Inc.

Brief Summary

This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species.

This study will compare the safety and efficacy of BACTELIDE in conjunction with standard of care (SOC) versus a placebo in conjunction with standard of care.

Detailed Description

The central aim of this study is to investigate the safety, tolerability, and indicative efficacy of a single dose of a phage therapy combination product, BACTELIDE, as an adjunct to standard therapy in participants presenting with a Stage II, III or IV pressure injuries with positive wound cultures for S. aureus, P. aeruginosa, or K. pneumoniae at screening.

Study Timeline

• Study First Submitted: 2021-03-19
• Study First Submitted QC: 2021-03-22
• Study First Posted: 2021-03-25
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-15
• Last Update Posted: 2021-12-21
• Study Start: 2022-01
• Primary Completion: 2023-08
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 69

Inclusion Criteria

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Stated willingness to comply with lifestyle considerations
4. Male or female, 18 years or older presenting in long-term care facilities, out-patient department or in-hospital patients with a stage II, III or IV pressure injury with or without local signs of infection with a size not exceeding 28 cm2
5. Within 72 hours before randomization, pressure injury specimen positive for S. aureus, P. aeruginosa, or K. pneumoniae determined by qPCR or rapid diagnostic test or conventional method or positive growth on specific agar.
6. For females of reproductive potential: use of a highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of administration of the study intervention
7. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria

1. Diagnosis of Kennedy terminal ulcer, Trombley-Brennan terminal tissue injuries or skin changes at life's end (SCALE).
2. Pregnancy or lactation.
3. Known allergic reactions to components of SilvaSorb hydrogel.
4. Known allergic reactions to components of the phage treatment; including known allergic reactions to bacteriophages, polyester amide urea polymers and/or TMN buffer.
5. Unstable coronary artery disease.
6. Patients diagnosed with Type I or Type II diabetes, uncontrolled (HgbA1c >8% or 2+ glycosuria).
7. Treatment with another investigational drug or other intervention within 30 days.
8. Intercurrent condition requiring a high dose of chronic corticosteroid therapy, immunosuppressive medication, oncologic chemotherapy.
9. Patients who have additional uncontrolled serious medical or psychiatric illness determined by the investigators where the patient is unfit to receive the product.
10. Chronic stool incontinence without a rectal tube if an individual has a sacral ulcer.
11. Placement of a wound vacuum.
12. Surgical wound closure planned within the study period.
13. Organ failure, acute respiratory failure and chronic renal failure.
14. Diagnosed osteomyelitis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Bacteriophage-loaded Microcapsule Spray with Standard of Care	Standard of Care	Phage therapy (Bacteriophage-loaded Microcapsule Spray) will be administered topically in conjunction with standard of care for pressure ulcers.
Placebo with Standard of Care	Placebo	Placebo, analogous to the experimental arm, will be administered topically in conjunction with standard of care for pressure ulcers.
Bacteriophage-loaded Microcapsule Spray with Standard of Care	Bacteriophage-loaded Microcapsule Spray	Phage therapy (Bacteriophage-loaded Microcapsule Spray) will be administered topically in conjunction with standard of care for pressure ulcers.
Placebo with Standard of Care	Standard of Care	Placebo, analogous to the experimental arm, will be administered topically in conjunction with standard of care for pressure ulcers.

Primary Outcome Measures

Name	Time	Method
Incidence of Treatment-Emergent Adverse Events coded by MedDra	At least 56 days	Safety of BACTELIDE will be measured by the number and percent of treatment related adverse events.
Incidence of treatment discontinuation due to adverse events	56 days	Tolerability of BACTELIDE will be measured by the percent premature discontinuation from the study intervention due to treatment emergent Adverse Events

Secondary Outcome Measures

Name	Time	Method
Assess the effect of BACTELIDE on the rate of wound progression.	56 days	Rate of wound progression will be measured by change in viable tissue.
Assess the effect of BACTELIDE on the incidence of bacterial colonization by S. aureus, P. aeruginosa, or K. pneumoniae species in pressure injury wounds.	28 days	Change in the incidence of positive wound cultures for S. aureus, P. aeruginosa, K. pneumoniae collected from surface deep wound swabs and /or tissue specimens.
Assess if BACTELIDE can improve the clinical outcome by preventing or treating wound infection.	28 days	Response/improvement in treatment-specific clinical outcome based on change in PUSH tool scores.